RxDoctor Payments Data

Bart Britten, MD

Family Medicine · Amarillo, TXNPI 1083757504

Payments from drug & device makers

$16,554in general payments, 2019–2025

Across 297 payments — averaging $55.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Roche Diabetes Care, Inc.$12K
  • AstraZeneca$750
  • Novo Nordisk$389
  • GSK$351
  • AbbVie$314
  • Boehringer Ingelheim$303
  • plus $2K from 36 others

What the payments were for

  • Food & beverage$4,517100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$16,554 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$240,780
Medicare patients
523
Services billed
9,283

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol137$112,720
OzempicSemaglutide97$103,461
MounjaroTirzepatide76$83,599
JanuviaSitagliptin Phosphate74$77,248
TradjentaLinagliptin76$70,261
JardianceEmpagliflozin76$65,541
EliquisApixaban47$46,520
MyrbetriqMirabegron34$21,166
Soliqua 100-33Insulin Glargine/Lixisenatide26$19,780
Breo ElliptaFluticasone/Vilanterol47$18,039
Janumet XrSitagliptin Phos/Metformin Hcl20$17,901
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$15,956
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog19$13,938
JanumetSitagliptin Phos/Metformin Hcl20$13,385
Jentadueto XrLinagliptin/Metformin Hcl12$11,628

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimTradjenta, Jardiance, Jentadueto Xr, Synjardy, Synjardy Xr$303$161,292188 claims
AstraZenecaFarxiga, Symbicort$750$116,138149 claims
MerckJanuvia, Janumet Xr, Janumet$150$108,534114 claims
Novo NordiskOzempic$389$103,46197 claims
Lilly USA, LLCMounjaro$126$83,59976 claims
PfizerEliquis, Premarin$234$49,14260 claims
GSKBreo Ellipta, Trelegy Ellipta$351$33,99671 claims
Astellas Pharma US IncMyrbetriq$235$21,16634 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$116$19,78026 claims
AbbVieSynthroid$314$3,21274 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Amarillo

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →